Endocrine Abstracts

Context: Clinical studies are needed to classify rare and novel RET mutations associated with hereditary medullary thyroid carcinoma (MTC) into one of three clinical risk groups.Objective: We analyzed genotype–phenotype correlations associated with the RET protooncogene mutation R770Q in exon 13 which was detected simultaneously with a Y791N mutation in the same family.Results: Calcitonin determination in a 43-year-old female ...

Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy with only limited effective systemic treatment options. The identification of actionable genetic lesions and its exploitation has expanded therapeutic approaches and especially for the subset of BRAFV600E mutated ATC (11-25%) combined BRAF- and MEK-inhibition indicated meaningful activity. Still, further effective therapeutic options are required for patients without identifiable driver mutations. The role ...

Therapeutic strategy for the management of radioiodine-refractory differentiated thyroid cancer (rrDTC) and advanced medullary thyroid cancer (MTC) had changed with the introduction of the multityrosine-kinase-inhibitors (MKI) sorafenib&lenvatinib and vandetanib&cabozantinib respectively. Only recently, the market approval of pralsetinib (FDA) and selpercatinib (FDA and EMA) as first highly selective RET(rearranged during transfection)- inhibitors have expande...

AUF1/heterogeneous nuclear ribonucleoprotein D (hnRNPD) is an adenylate uridylate-rich elements (ARE) binding protein, which regulates the mRNA stability of many genes related to growth regulation, such as proto-oncogenes, growth factors, cytokines and cell cycle regulatory genes. Several studies demonstrated AUF1 expression in kidneys, liver, lymphoid tissues and melanocytes, and its involvement in apoptosis, tumorigenesis and development by its interactions with AREs bearing...

Retinoic acid (RA) acts as an anti-proliferative and re-differentiation agent in the therapy of thyroid carcinoma but the molecular mechanisms by which RA mediates these effects are not well understood. We have investigated the effect of RA on the production and post-translational modification of the two ENO1 transcriptional products in the human follicular thyroid carcinoma cell line FTC-133. The single ENO1 transcript encodes a 48 kDa ENO1 with its unique N-terminal enolase ...